Phosphodiesterase 3, 4 and 7 inhibitors (Spring Bank Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NamePhosphodiesterase 3, 4 and 7 inhibitors (Spring Bank Pharmaceuticals)

Drug Alias NameNucleotide based program (Spring Bank Pharmaceuticals)Small molecule nucleic acid hybrids (Spring Bank Pharmaceuticals)SMNH compounds (Spring Bank Pharmaceuticals)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives

Mechanisms of ActionPhosphodiesterase 3 inhibitorsPhosphodieterase 4 inhibitorsPhosphodiesterase 7 inhibitors +[4]

TargetsCathelicidin antimicrobial peptidePhosphodiesterase 3Phosphodiesterase 7 +[4]

Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSpring Bank Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSpring Bank Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A